Regeneron (NASDAQ: REGN) controller sells $3.83 million of stock after option exercise

What happened

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) SVP Controller Jason Pitofsky sold 4,062 shares on Nov. 4 for about $3.83 million.

Pitofsky exercised stock options on 1,500, 1,478 and 905 shares the same day. A Form 4 signed Nov. 6 reports the exercises and the sales together. The form lists eight sales at volume-weighted average prices from $939.57 to $950.76 a share.

The last sale line, for 179 shares, falls under holdings by a spouse, which show 0 shares afterward. After the seven other sales, the table shows 4,272 shares held directly. A separate line lists 48 shares in a 401(k) plan.

Key numbers

Metric	Latest	Change	Source
Shares sold	4,062 shares		SEC Form 4
Total sale value	about $3.83 million		SEC Form 4
Average sale price range per share	$939.57 to $950.76		SEC Form 4
Shares held directly after the seven direct sales	4,272 shares		SEC Form 4
Shares held in 401(k) plan	48 shares		SEC Form 4

Read more: Regeneron Pharmaceuticals (REGN) company research

Why it matters

The trade leaves OptimistFi's view of Regeneron unchanged. OptimistFi has argued that Regeneron turns its homegrown pipeline and in-house manufacturing into repeatable cash flow from core products, which funds research and supports earnings-per-share growth. One officer exercising options and selling shares does not alter how those products earn money.

The options carried exercise prices well below the sale prices. The filing says the options vested in four equal annual installments starting one year after grant, which points to the exercise of awards that had already vested.

The exercises came in three tranches. Options on 1,500 shares carried the $726.53 price, options on 1,478 shares carried $644.54, and options on 905 shares carried $492, according to the Form 4. The lowest-priced tranche therefore had the widest gap to the sale prices.

The sale also reduces the position rather than closing it. Pitofsky still holds shares directly, and options on 500 and 2,478 shares remain from the two later grants. Those options expire Dec. 8, 2031 and Dec. 16, 2032. The Form 4 also shows 48 shares held in a 401(k) plan, separate from the direct holding.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The next test is Regeneron's next quarterly report. Steady cash flow from core products and continued research funding would support OptimistFi's view, while weaker cash generation would challenge it.

More from OptimistFi

• REGN stock: research and coverage of Regeneron Pharmaceuticals
• Stock research on every company OptimistFi covers

From OptimistFi Perps